Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2014 2
2015 4
2016 5
2017 2
2019 4
2020 6
2021 12
2022 5
2023 7
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

41 results

Results by year

Filters applied: . Clear all
Page 1
Conversion Surgery for Unresectable Pancreatic Cancer Treated With FOLFIRINOX or Gemcitabine Plus Nab-paclitaxel.
Ide Y, Otsuka T, Shimokawa M, Koga F, Ueda Y, Nakazawa J, Komori A, Otsu S, Arima S, Fukahori M, Makiyama A, Shinohara Y, Ueno S, Taguchi H, Honda T, Shibuki T, Nio K, Ureshino N, Mizuta T, Mitsugi K, Shirakawa T. Ide Y, et al. Among authors: fukahori m. Anticancer Res. 2023 Apr;43(4):1817-1826. doi: 10.21873/anticanres.16335. Anticancer Res. 2023. PMID: 36974805
Erythema multiforme induced by regorafenib.
Matsunaga M, Ushijima T, Fukahori M, Tanikawa K, Miwa K. Matsunaga M, et al. Among authors: fukahori m. J Gen Fam Med. 2017 Mar 24;18(2):90-91. doi: 10.1002/jgf2.29. eCollection 2017 Apr. J Gen Fam Med. 2017. PMID: 29263999 Free PMC article. No abstract available.
Efficacy of second-line chemotherapy after treatment with gemcitabine plus nab-paclitaxel or FOLFIRINOX in patients with metastatic pancreatic cancer.
Fukahori M, Okabe Y, Shimokawa M, Otsuka T, Koga F, Ueda Y, Nakazawa J, Komori A, Otsu S, Arima S, Makiyama A, Taguchi H, Honda T, Ushijima T, Miwa K, Shibuki T, Nio K, Ide Y, Ureshino N, Mizuta T, Mitsugi K, Shirakawa T. Fukahori M, et al. Sci Rep. 2023 Nov 8;13(1):19399. doi: 10.1038/s41598-023-46924-0. Sci Rep. 2023. PMID: 37938630 Free PMC article.
C-reactive protein/albumin ratio is the most significant inflammatory marker in unresectable pancreatic cancer treated with FOLFIRINOX or gemcitabine plus nab-paclitaxel.
Shirakawa T, Makiyama A, Shimokawa M, Otsuka T, Shinohara Y, Koga F, Ueda Y, Nakazawa J, Otsu S, Komori A, Arima S, Fukahori M, Taguchi H, Honda T, Shibuki T, Nio K, Ide Y, Ureshino N, Mizuta T, Mitsugi K, Akashi K, Baba E. Shirakawa T, et al. Among authors: fukahori m. Sci Rep. 2023 May 31;13(1):8815. doi: 10.1038/s41598-023-34962-7. Sci Rep. 2023. PMID: 37258608 Free PMC article.
Left-sided inferior vena cava.
Matsunaga M, Fukahori M, Ushijima T, Miwa K. Matsunaga M, et al. Among authors: fukahori m. BMJ Case Rep. 2015 Jun 8;2015:bcr2015211268. doi: 10.1136/bcr-2015-211268. BMJ Case Rep. 2015. PMID: 26055610 Free PMC article. No abstract available.
Hyperlipidemia as a risk factor for Trousseau syndrome-related cerebral infarction in patients with advanced gastrointestinal cancer.
Tanaka T, Suzuki H, Miwa K, Ushijima T, Nagasu S, Fukahori M, Ishii K, Nakamura T, Iwamoto H, Masuda A, Sakaue T, Koga H, Akagi Y, Murotani K, Torimura T. Tanaka T, et al. Among authors: fukahori m. Oncol Lett. 2022 Jul 19;24(3):318. doi: 10.3892/ol.2022.13437. eCollection 2022 Sep. Oncol Lett. 2022. PMID: 35949619 Free PMC article.
A circumaortic left renal vein.
Matsunaga M, Ushijima T, Fukahori M, Miwa K. Matsunaga M, et al. Among authors: fukahori m. BMJ Case Rep. 2015 Sep 11;2015:bcr2015212528. doi: 10.1136/bcr-2015-212528. BMJ Case Rep. 2015. PMID: 26361807 Free PMC article. No abstract available.
Gemcitabine Plus Nanoparticle Albumin-bound Paclitaxel Versus FOLFIRINOX for Recurrent Pancreatic Cancer After Resection.
Taguchi H, Otsuka T, Shimokawa M, Arima S, Hashimoto S, Ido A, Koga F, Ueda Y, Nakazawa J, Komori A, Otsu S, Fukahori M, Makiyama A, Honda T, Shibuki T, Mizuta T, Mitsugi K, Nio K, Ide Y, Ureshino N, Shirakawa T. Taguchi H, et al. Among authors: fukahori m. Anticancer Res. 2021 Jul;41(7):3573-3582. doi: 10.21873/anticanres.15145. Anticancer Res. 2021. PMID: 34230153
41 results